Overview

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
Giselle SaulnierSholler
Giselle Sholler
Collaborator:
Bayer
Treatments:
Cyclophosphamide
Nifurtimox
Topotecan